Melatonin Sleep Latency Randomized Trial: What the Evidence Says

Quick Answer

Melatonin Sleep Latency Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Evidence from a recent meta-analysis of sleep disorders indicates that insomnia affects approximately 25% of the Indian population, and nearly 15% of otherwise healthy individuals report sleep-related problems such as insomnia and obstructive sleep apnea, highlighting sleep disturbances as an important and potentially underrecognized public health concern in the country. [Thanawala Shefali (2026); evidence level 2]
• Poor sleep quality, characterized by prolonged sleep latency and frequent nocturnal awakenings, is associated with increased fatigue and has been linked to a broad range of adverse health outcomes, including impairments in attention, memory, and learning, as well as an increased risk of mood disorders (such as anxiety and depression) and metabolic disorders (including obesity and diabetes). [Thanawala Shefali (2026); evidence level 2]
• Sleep is a complex biological process whose evolutionary purpose has remained equivocal for quite some time.More recently, however, compelling evidence has emerged, leading to recognition of the numerous metabolic and physiological functions sleep contributes to and actively supports. [Conti Federica (2026); evidence level 4]
• Epidemiological studies have revealed that sleep deprivation is associated with an increased risk of all-cause mortality,alongside numerous chronic conditions imposing a heavy burden on our healthcare and socioeconomic systems alike,including cardiovascular disease, stroke, obesity, type 2 diabetes, and various types of cancer and neurological disorders. [Conti Federica (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For melatonin sleep latency randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Thanawala Shefali (2026). Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial. DOI: 10.3390/clockssleep8020031. PMCID: PMC13297780. PMID: 42345841. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13297780/
• Conti Federica (2026). Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. DOI: 10.1093/nutrit/nuaf062. PMCID: PMC13075487. PMID: 40418260. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13075487/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.